

## Jonathan Davies

Partner



jdavies@cooley.com

+1 202 776 2049

Washington, DC

Intellectual Property Litigation

Life Sciences IP Litigation

Intellectual Property

Dr. Jonathan Davies' practice focuses on patent litigation with an emphasis on pharmaceutical and biotechnology cases, including Hatch-Waxman litigation related to Abbreviated New Drug Applications (ANDAs) and biologics litigation under the Biologics Price Competition and Innovation Act (BPCIA).

Jonathan's litigation experience includes all aspects of pre-trial and trial district court practice. He also has experience advising clients in infringement and validity opinions.

Prior to law school, Jonathan completed graduate studies in human physiology and conducted doctoral and post-doctoral research in cellular and molecular biology and genetics. His research focused on molecular mechanisms that regulate cellular growth and division, as well as the regulation of nuclear transport within cells.

Jonathan's pro bono practice includes representing a mother in a child custody case in DC Superior Court. He represented a student in litigation related to the improper destruction of his home in DC Superior Court and US District Court for the District of Columbia.

Jonathan serves as an adjunct professor at American University Washington College of Law, where he teaches a course on ANDA litigation and biosimilars litigation under BPCIA.

### Recent Representative Experience

*\*representation prior to joining Cooley*

- ***BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc. and Teva Pharmaceutical Industries Ltd. (D. Del)***  
Represented BDSI in Hatch-Waxman litigation concerning its Belbuca® product for the management of pain.
- ***BioDelivery Sciences International, Inc. v. Actavis Laboratoires UT, Inc. and Actavis Inc. (D. Del)***  
Represented BDSI in Hatch-Waxman litigation concerning its Bunavail® product for maintenance treatment of opioid dependence.
- ***United Therapeutics Corp. v. Liquidia Technologies***  
Representing Liquidia in Hatch-Waxman litigation concerning Liquidia's 505(b)(2) NDA for inhaled powder treprostinil for the treatment of pulmonary arterial hypertension.

- ***Journey Medical Corp. and Rose U v. Perrigo***  
Representing Journey Medical in a Hatch-Waxman litigation concerning Journey's Qbrexza® ((glycopyrronium cloth) product for the treatment of primary axillary hyperhidrosis) against ANDA filer Perrigo.
- ***Shire ViroPharma Inc. v. CSL Behring LLC\****  
Representing defendant CSL Behring in patent litigation concerning its biologic Haegarda® for the prophylactic prevention of hereditary angioedema.
- ***AbbVie Inc. v. Boehringer Ingelheim International GmbH\****  
Represented AbbVie in Biologics Price Competition and Innovation (BPCIA) litigation related to Humira®.
- ***Allergan/Forest Laboratories v. Sigmapharm Laboratories, LLC\****  
Represented Forest Labs in ANDA litigation for its Saphris® (asenapine) product for the treatment of schizophrenia and bipolar disorder against multiple generic drug manufacturers.
- ***AbbVie Inc. and AbbVie Deutschland GmbH & Co. KG v. Hetero USA Inc. and Hetero Labs Ltd.\****  
Represented AbbVie in ANDA litigation related to its Norvir® products for the treatment of HIV against multiple generic drug manufacturers in both the Southern District of Ohio and the District of Delaware.
- ***AbbVie Inc. v. Mylan Laboratories, Inc.\****  
Represented AbbVie in ANDA litigation related to its Kaletra® products for the treatment of HIV against multiple generic drug manufacturers.
- ***Astellas US LLC v. Nycomed US Inc.\****  
Represented Astellas in ANDA litigation related to its immunosuppressant drug Protopic®.
- ***Eli Lilly & Co. v. Wockhardt Ltd.\****  
Represented Eli Lilly in ANDA litigation related to its Cymbalta® product against multiple generic drug manufacturers.

#### Publications

- "FDA Opens Useful Dialogue on Orange Book Patent Listings" Law 360 (June 2020). Co-Author.
- "Follow-On Biologics: Is Your Patent Portfolio Ready?" Law360 (March 2010). Co-Author.
- "Follow-On Biologics: A Patent Litigation Perspective" Pharmaceutical Commerce (August 2009). Co-Author.

#### Education

The Ohio State University, Moritz College of Law  
JD, 2008, *magna cum laude*

The Ohio State University  
PhD, 2004, Molecular Genetics

Pennsylvania State University  
MS, 1999, Physiology

Grove City College  
BS, 1997, Biology

## Admissions & Credentials

District of Columbia

Maryland

## Court Admissions

U.S. Court of Appeals, Federal Circuit

## Memberships

American Intellectual Property Law Association

Order of the Coif